Pheon Hopes To Stir Up ADC Space With First-In-Class Compound

Launches With $68m Series A

The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.

Bertrand Damour
Bertrand Damour • Source: Pheon

The hot area of antibody-drug conjugates (ADCs) is getting a new player with the launch of Pheon Therapeutics, a UK-based biotech that comes armed with a sizeable cash pile and a hugely experienced senior management team.

More from Financing

More from Business